Compare Cytokinetics Inc (CYTK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Merck & Co., Inc. — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Merck & Co., Inc. trades at $123.25 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 26.8× Cytokinetics Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MRK | |
|---|---|---|
Market Cap | $11.12B | $298.31B |
Sector | Technology | Health |
52-Week High | $87.26 | $129.52 |
52-Week Low | $33.23 | $77.60 |
Enterprise Value | $11.59B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Merck (MRK) trades at $124.03, up 0.4% on the day, with a bullish technical signal and strong analyst support. The company reported solid earnings beats in recent quarters, including Q1 2026's better-than-expected loss, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth efforts amid competitive pressures.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include patent expirations and rising debt. With a consensus price target of $137.30 offering ~11% upside, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic and regulatory headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
